23 / 52
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
VOLUME 13 NUMBER 2 • DECEMBER 2016
73
Conclusion
This meta-analysis suggested that, compared with BMS, SES are
more effective and safer for reducing major cardiac events in CAD
patients with diabetes. This may indicate the direction for future
trials and clinical implementation.
References
1. Nodari S, Manerba A, Vaccari A, Milesi G, Carubelli V, Lazzarini V,
et al
. Six-year
prognosis of diabetic patients with coronary artery disease.
Eur J Clin Invest
2012;
42
(4): 376–383.
2. Van Nunen LX, Tonino PA. Recent insights into the treatment of stable CAD: FFR-
guided PCI vs. medical therapy.
Herz
2013. 2013 Apr 17. [Epub ahead of print].
3. Haase J, Jung T, St.rger H, Hofmann M, Reinemer H, Schwarz CE,
et al
. Long-term
outcome after implantation of bare metal stents for the treatment of coronary
artery disease: rationale for the clinical use of antiproliferative stent coatings.
J
Interv Cardiol
2003;
16
(6): 469–473.
4. Lemos PA, Bienert I. The Supralimus. sirolimus-eluting stent.
Expert Rev Med
Devices
2013. 2013 Apr 18. [Epub ahead of print].
5. Hsieh IC, Chang SH, Wang CY, Lee CH, Lin FC, Chen CC. Acute and long-term
outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents,
and paclitaxel-eluting stents.
Coron Artery Dis
2013;
24
(3): 224–230.
6. Obata JE, Nakamura T, Kitta Y, Saito Y, Sano K, Fujioka D, Kawabata KI,
et al
.
In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-
eluting stent to treat a long de novo coronary lesion with small distal vessel
diameter.
Catheter Cardiovasc Interv
2013. 2013 Feb 4. doi: 10.1002/ccd.24841.
[Epub ahead of print].
7. Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K, Macours N,
et
al
. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized,
blinded comparison of sirolimuseluting NEVO stents with paclitaxel-eluting
TAXUS Libert. stents in de novo native coronary artery lesions.
Circ Cardiovasc
Interv
2011;
4
(2): 146–154.
8. Jim.nez-Quevedo P, Sabat. M, Angiolillo DJ, Costa MA, Alfonso F, G.mez-Hospital
JA, Hern.ndez-Antol.n R,
et al
.; DIABETES Investigators. Vascular effects of
sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional
ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial.
J
Am Coll Cardiol
2006;
47
(11): 2172–2179.
9. De Luca G, Dirksen MT, Spaulding C, Kelb.k H, Schalij M, Thuesen L, van der
Hoeven B,
et al
.; DESERT Cooperation. Meta-analysis comparing efficacy and
safety of first generation drug-eluting stents to baremetal stents in patients with
diabetes mellitus undergoing primary percutaneous coronary intervention.
Am J
Cardiol
2013;
111
(9): 1295–1304.
10. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO,
et al
. Outcomes with various drug eluting or bare metal stents in patients with
diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years
of follow-up from randomised trials.
Br Med J
2012;
345
: e5170.
11. Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, Drexler H,
et
al
.; SCORPIUS Study. Five-year results of the Multicenter Randomized Controlled
Open-Label Study of the CYPHER Sirolimus- Eluting Stent in the Treatment of
Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study:
a German multicenter investigation on the effectiveness of sirolimus-eluting
stents in diabetic patients.
Am Heart J
2012;
163
(3): 446–453.
12. Aoki J, Ong A, Rodriguez-Granillo G, Van Mieghem C, Daemen J, Sonnenschein
K, McFadden E,
et al
. The efficacy of sirolimus-eluting stents versus bare
metal stents for diabetic patients undergoing elective percutaneous coronary
intervention.
J Invasive Cardiol
2005;
17
(7): 344–348.
13. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P,
et al
.; DESSERT Investigators. Comparison of effectiveness and safety of sirolimus-
eluting stents versus bare-metal stents in patients with diabetes mellitus (from
the Italian Multicenter Randomized DESSERT Study).
Am J Cardiol
2008;
101
(11):
1560–1566.
14. Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M;
DECODE investigators. A randomized comparison of sirolimus-eluting versus bare
metal stents in the treatment of diabetic patients with native coronary artery
lesions: the DECODE study.
Catheter Cardiovasc Interv
2008;
72
(5): 591–600.
15. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H,
et al
.;
SCORPIUS study investigators. One-year results of the SCORPIUS study: a German
multicenter investigation on the effectiveness of sirolimus-eluting stents in
diabetic patients.
J Am Coll Cardiol
2007;
50
(17): 1627–1634.
16. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van
Domburg RT,
et al
. The long-term value of sirolimus- and paclitaxel-eluting stents
over bare metal stents in patients with diabetes mellitus.
Eur Heart J
2007;
28
(1):
26–32.
17. DerSimonian R. Meta-analysis in clinical trials.
Control Clin Trials
1986;
7
(3): 177–
188.
18. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials.
Stat
Med
1996
15
(12): 1237–1248.
19. Klebanoff MA, Levine RJ, DerSimonian R. Large trials vs meta-analysis of smaller
trials.
J Am Med Assoc
1997;
277
(5): 376–377.
20. Geller N, Freedman L, Lee YJ, DerSimonian R. Conference on metaanalysis in the
design and monitoring of clinical trials.
Stat Med
1999;
18
(6): 753–754.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA group. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
PLoS
Med
2009;
6
(7): e1000097.
22. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J,
et al
.
Recommendations for examining and interpreting funnel plot asymmetry in
meta-analyses of randomised controlled trials.
Br Med J
2011;
343
: D4002.
23. DerSimonian R, Levine RJ.. Resolving discrepancies between a metaanalysis and a
subsequent large controlled trial.
J Am Med Assoc
1999;
282
(7): 664–670.
24. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical
trials: an update.
Contemp Clin Trials
2007;
28
(2): 105–114.
25. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects metaanalyses.
Br
Med J
2011;
342
(d549).
26. Moreno SG, Sutton AJ, Thompson JR, Ades AE, Abrams KR, Cooper NJ. A
generalized weighting regression-derived meta-analysis estimator robust to
small-study effects and heterogeneity.
Stat Med
2012;
31
(14): 1407–1417.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med
2002;
21
(11): 1539–1558.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected
by a simple, graphical test.
Br Med J
1997;
315
(7109): 629–634.
29. Jim.nez-Quevedo P, Hernando L, G.mez-Hospital JA, I.iguez A, Sanroman A,
Alfonso F, Hern.ndez-Antol.n R,
et al
. Sirolimus-eluting stent versus bare metal
stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
EuroIntervention
2013; 2013 Mar 22. pii: 20120620-01. [Epub ahead of print].
30. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C.
Long-term clinical and angiographic results of Sirolimus-Eluting Stent in Complex
Coronary Chronic Total Occlusion Revascularization: the SECTOR registry.
J Interv
Cardiol
2011;
24
(5): 426–436.
31. De Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Sch.mig
A, Kastrati A. Long-term outcome after sirolimus-eluting stents versus bare
metal stents in patients with diabetes mellitus: a patient-level meta-analysis of
randomized trials.
Clin Res Cardiol
2011;
100
(7): 561–570.
32. Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ, Simonton
CA,
et al
; ACROSS/TOSCA-4 investigators. Clinical and angiographic outcomes
with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4
(Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion
Study of Coronary Arteries-4) trial.
J Am Coll Cardiol Cardiovasc Interv
2009;
2
(2):
97–106.
33. Byrne RA, Kastrati A. Is there a preferable DES in diabetic patients? A critical
appraisal of the evidence.
Catheter Cardiovasc Interv
2008;
72
(7): 944–949.
34. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken
and interpreted?
Stat Med
2002;
21
(11): 1559–1573.
35. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines
on choice of axis.
J Clin Epidemiol
2001;
54
(10): 1046–1055.
36. Zwahlen M, Renehan A, Egger M. Meta-analysis in medical research: potentials
and limitations.
Urol Oncol
2008;
26
(3): 320–329.